AOP2 AND ATHEROSCLEROSIS RESISTANCE AND MICE
AOP2 和动脉粥样硬化抵抗与小鼠
基本信息
- 批准号:6343492
- 负责人:
- 金额:$ 3.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-12-12 至
- 项目状态:未结题
- 来源:
- 关键词:animal breeding atherosclerosis disease /disorder model gene expression genetic promoter element genetic susceptibility genetically modified animals in situ hybridization laboratory mouse model design /development molecular cloning nucleic acid sequence oxidative stress polymerase chain reaction tissue /cell culture
项目摘要
DESCRIPTION
Previous studies from our laboratory have demonstrated that susceptibility
to atherosclerosis differs significantly between inbred strains of mice,
suggesting a strong genetic component to the disease. Athl is a
quantitative trait locus that we found to be associated with decreased
plasma HDL-cholesterol levels and increased atherosclerotic lesion
formation in susceptible strains of mice when fed a high fat diet. We have
recently identified a Athl candidate gene, Aop2, which is a member of the
thiol-specific antioxidant family. We believe Aop2 mediates protection
from atherosclerosis based on its chromosomal co-localization with Athl,
mRNA induction by high fat diet, amino acid and expression differences
between resistant and susceptible strains, and the proposed role of LDL
oxidation in the pathogenesis of atherosclerosis. I propose three specific
aims toward the characterization of AOP2 in atherosclerosis resistance: 1)
obtain definitive proof that AOP2 confers resistance to atherosclerosis by
transgenic rescue; 2) characterize expression of AOP2 in the arterial
wall; and 3) determine the molecular basis for the regulatory differences
observed between atherosclerosis resistant and susceptible strains.
描述
项目成果
期刊论文数量(17)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Muscarinic cholinergic receptors in developing rat lung.
发育中的大鼠肺中的毒蕈碱胆碱能受体。
- DOI:10.1203/00006450-198411000-00016
- 发表时间:1984
- 期刊:
- 影响因子:3.6
- 作者:Whitsett,JA;Hollinger,B
- 通讯作者:Hollinger,B
Biophysical activity of synthetic phospholipids combined with purified lung surfactant 6000 dalton apoprotein.
合成磷脂与纯化的肺表面活性剂 6000 道尔顿脱辅基蛋白结合的生物物理活性。
- DOI:10.1016/0009-3084(87)90002-8
- 发表时间:1987
- 期刊:
- 影响因子:3.4
- 作者:Notter,RH;Shapiro,DL;Ohning,B;Whitsett,JA
- 通讯作者:Whitsett,JA
Intracellular and oligomeric forms of surfactant-associated apolipoproteins(s) A in the rat.
大鼠体内表面活性剂相关载脂蛋白 A 的细胞内和寡聚形式。
- DOI:10.1016/0167-4838(85)90210-9
- 发表时间:1985
- 期刊:
- 影响因子:0
- 作者:Weaver,TE;Hull,WM;Ross,GF;Whitsett,JA
- 通讯作者:Whitsett,JA
Glycosylation and secretion of surfactant-associated glycoprotein A.
- DOI:10.1016/s0021-9258(18)95731-5
- 发表时间:1985-12
- 期刊:
- 影响因子:0
- 作者:J. Whitsett;G. Ross;T. Weaver;W. Rice;C. Dion;W. Hull
- 通讯作者:J. Whitsett;G. Ross;T. Weaver;W. Rice;C. Dion;W. Hull
Structural relationships of the major glycoproteins from human alveolar proteinosis surfactant.
人肺泡蛋白沉积表面活性剂主要糖蛋白的结构关系。
- DOI:10.1016/0167-4838(87)90070-7
- 发表时间:1987
- 期刊:
- 影响因子:0
- 作者:Ross,GF;Ohning,BL;Tannenbaum,D;Whitsett,JA
- 通讯作者:Whitsett,JA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shelley A Phelan其他文献
Shelley A Phelan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shelley A Phelan', 18)}}的其他基金
AOP2 AND ATHEROSCLEROSIS RESISTANCE AND MICE
AOP2 和动脉粥样硬化抵抗与小鼠
- 批准号:
2767602 - 财政年份:1999
- 资助金额:
$ 3.92万 - 项目类别:
AOP2 AND ATHEROSCLEROSIS RESISTANCE AND MICE
AOP2 和动脉粥样硬化抵抗与小鼠
- 批准号:
6139127 - 财政年份:1999
- 资助金额:
$ 3.92万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 3.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别:
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS - TOPMED
动脉粥样硬化的多种族研究 - TOPMED
- 批准号:
10974007 - 财政年份:2023
- 资助金额:
$ 3.92万 - 项目类别: